Ranibizumab: The Clinician?s Guide to Commencing, Continuing, and Discontinuing Treatment

Abstract

The National Institute for Health and Clinical Excellence (NICE) Guidance has recommendded ranibizumab in the treatment of wet age related macular degeneration (AMD). The Institute further recommended that a national protocol specifying criteria for discontinuation of ranibizumab is developed. Criteria for discontinuation should include persistent deterioration in visual acuity and identifi-cation of anatomical changes in the retina that indicate inadequate response to therapy.

The Royal College of Ophthalmologists (RCOphth) recognised the need for such guidance and brought together a group of clinicians with expertise in the treatment of AMD with ranibizumab, NICE